Shire PLC (LON:SHP)‘s stock had its “buy” rating reaffirmed by analysts at Bryan, Garnier & Co in a report issued on Monday. They currently have a GBX 6,900 ($85.40) price target on the biopharmaceutical company’s stock. Bryan, Garnier & Co’s price objective would suggest a potential upside of 33.44% from the company’s current price.

Other analysts have also issued research reports about the stock. HSBC lowered their target price on shares of Shire PLC from GBX 5,250 ($64.98) to GBX 5,200 ($64.36) and set a ” hold” rating for the company in a research note on Wednesday, September 28th. Deutsche Bank AG reiterated a “buy” rating and set a GBX 6,000 ($74.26) target price on shares of Shire PLC in a research note on Wednesday, July 13th. Liberum Capital reiterated a “buy” rating and set a GBX 5,500 ($68.07) target price on shares of Shire PLC in a research note on Tuesday, July 12th. Goldman Sachs Group Inc. reiterated a “buy” rating and set a GBX 6,300 ($77.97) target price on shares of Shire PLC in a research note on Tuesday, July 12th. Finally, Berenberg Bank reiterated a “buy” rating and set a GBX 5,800 ($71.78) target price on shares of Shire PLC in a research note on Wednesday, July 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eighteen have given a buy rating to the company. Shire PLC currently has a consensus rating of “Buy” and an average price target of GBX 5,907.50 ($73.11).

Analyst Recommendations for Shire PLC (LON:SHP)

Shire PLC (LON:SHP) opened at 5128.00 on Monday. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00. The stock has a 50 day moving average of GBX 5,005.03 and a 200-day moving average of GBX 4,600.81. The stock’s market cap is GBX 35.01 billion.

The firm also recently declared a dividend, which was paid on Friday, October 7th. Shareholders of record on Thursday, September 8th were issued a GBX 3.51 ($0.04) dividend. This represents a yield of 0.07%. The ex-dividend date of this dividend was Thursday, September 8th.

In other Shire PLC news, insider Dominic Blakemore purchased 133 shares of the business’s stock in a transaction on Friday, September 30th. The stock was bought at an average cost of GBX 5,010 ($62.00) per share, with a total value of £6,663.30 ($8,246.66).

Shire PLC Company Profile

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.